Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia
Status:
Recruiting
Trial end date:
2022-03-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if CVI-LM001 is effective and safe versus placebo
in drug-naive subjects with elevated LDL cholesterol. There will be 4 groups receiving 100mg,
200mg, 300 mg and placebo treatment for 12 weeks respectively.